The pharmaceutical industry is under fire in the public eye, in Congress and in the courts. And it mostly brought this on itself — through price hikes, allegedly anticompetitive behavior and aggressive opioid marketing.
The big picture: There's a real debate to be had about the value of new, innovative, sometimes life-saving drugs. But the industry has clouded its own argument, and weakened its own political standing, through a slew of bad behavior.
Ambulnz, a startup that dispatches non-emergency ambulances, has filed paperwork with the Securities and Exchange Commission to raise $90 million in outside funding. The company did not respond to multiple attempts for comment.
The bottom line: Ambulnz is seeking a lot of cash, but it's unclear how the company operates.
